Marnix C. Maas1,
Marit J. Koopman1, Geert J.S. Litjens1, Alan J. Wright1,
Kirsten M. Selns2, Ingrid Susann Gribbestad2, Masoom
A. Haider3, Katarzyna J. Macura4, Daniel J.A. Margolis5,
Berthold Kiefer6, Jurgen J. Ftterer1, Tom W.J.
Scheenen1
1Department
of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands; 2Department of Circulation and Medical Imaging,
Norwegian University of Science and Technology, Trondheim, Norway; 3Joint
Department of Medical Imaging, Princess Margaret Hospital, University Health
Network and Mount Sinai Hospital, Toronto, ON, Canada; 4Russel H.
Morgan Department of Radiology and Radiological Science, Johns Hopkins
University, Baltimore, MD, United States; 5Department of
Radiology, UCLA David Geffen School of Medicine, Los Angeles, CA, United
States; 6Siemens AG Healthcare Sector, Erlangen, Germany
This work presents initial results of a multi-center trial aimed at assessing the diagnostic accuracy of 3T multi-parametric MR imaging and spectroscopy (mpMRI) in distinguishing clinically significant prostate cancer from other prostatic tissue, with whole-mount section histopathology as the gold standard. Multi-center mpMRI with identical protocols at 3T without ERC provided homogeneous quantitative parameters for non-cancer tissues and detected significant differences between these tissues. The validation part of this prospective trial will be used to determine the parameters contributing most to the detection and localization of clinically significant PCa as well as their optimal cutoff values.